4D Molecular Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Depreciation & Amortization Growth & History (FDMT)
4D Molecular Therapeutics's depreciation and amortization was $4.7M for fiscal 2025.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.7M | $41,000 | +0.88% |
| 2024 | 2024-12-31 | $4.7M | $449,000 | +10.68% |
| 2023 | 2023-12-31 | $4.2M | $1.8M | +74.95% |
| 2022 | 2022-12-31 | $2.4M | $880,000 | +57.78% |
| 2021 | 2021-12-31 | $1.5M | $80,000 | +5.54% |
| 2020 | 2020-12-31 | $1.4M | $439,000 | +43.73% |
| 2019 | 2019-12-31 | $1.0M | — | — |
4D Molecular Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.3M | $114,000 | +9.78% |
| Q1 2026 | 2026-03-31 | $1.3M | $218,000 | +20.74% |
| Q4 2025 | 2025-12-31 | $2.0M | — | — |
| Q3 2025 | 2025-09-30 | $1.3M | $71,000 | +5.97% |
| Q2 2025 | 2025-06-30 | $1.2M | −$28,000 | −2.35% |
| Q1 2025 | 2025-03-31 | $1.1M | −$122,000 | −10.40% |
| Q3 2024 | 2024-09-30 | $1.2M | $196,000 | +19.72% |
| Q2 2024 | 2024-06-30 | $1.2M | $115,000 | +10.66% |
| Q1 2024 | 2024-03-31 | $1.2M | $144,000 | +13.99% |
| Q3 2023 | 2023-09-30 | $994,000 | $477,000 | +92.26% |
| Q2 2023 | 2023-06-30 | $1.1M | $613,000 | +131.55% |
| Q1 2023 | 2023-03-31 | $1.0M | $623,000 | +153.45% |
| Q3 2022 | 2022-09-30 | $517,000 | $137,000 | +36.05% |
| Q2 2022 | 2022-06-30 | $466,000 | $96,000 | +25.95% |
| Q1 2022 | 2022-03-31 | $406,000 | $23,000 | +6.01% |
| Q3 2021 | 2021-09-30 | $380,000 | $11,000 | +2.98% |
| Q2 2021 | 2021-06-30 | $370,000 | $11,000 | +3.06% |
| Q1 2021 | 2021-03-31 | $383,000 | $39,000 | +11.34% |
| Q3 2020 | 2020-09-30 | $369,000 | — | — |
| Q2 2020 | 2020-06-30 | $359,000 | — | — |
| Q1 2020 | 2020-03-31 | $344,000 | — | — |
4D Molecular Therapeutics depreciation and amortization trends
Over the last five fiscal years, 4D Molecular Therapeutics's depreciation and amortization increased from $1.4M to $4.7M, a change of $3.3M. The latest reported quarter, Q2 2026, shows $1.3M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 4D Molecular Therapeutics source filings ↗